The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FGFR2 inhibition could suppress spermatogenesis.
 
Ilya Tsimafeyeu
Leadership - Ruspharmtech
Stock and Other Ownership Interests - Ruspharmtech
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Ruspharmtech
Research Funding - Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Kidney Cancer Research Bureau; Oncomax LLC; Ruspharmtech
 
Nataliya Lapina
No Relationships to Disclose
 
Mikhail Byakhov
Stock and Other Ownership Interests - Ruspharmtech
 
Nadezhda Dragun
Employment - Ruspharmtech
 
Evgenia Gavrilova
Employment - Ruspharmtech
 
Anastasia Skorobogatova
Employment - Ruspharmtech
 
Kira Stosman
No Relationships to Disclose
 
Marina Melikhova
No Relationships to Disclose
 
Olga Vakunenkova
No Relationships to Disclose
 
Vadim Kashuro
No Relationships to Disclose
 
Mikhail Rozhko
No Relationships to Disclose
 
Sergei Tjulandin
Stock and Other Ownership Interests - RosPharmTech
Speakers' Bureau - AstraZeneca; BioCad; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche